Chinese firms sell HPV shots that cost about 300 yuan ($41), one-tenth the price of Gardasil. While those cheaper vaccines don’t cover as many viral strains as Merck’s, the country’s ...

We're maintaining our $111 fair value estimate for wide-moat Merck following a quarter that held both expected Gardasil declines as well as impressive sales of newer products like vaccine ...

Gardasil sales fell 41% in the first quarter, in line with analysts’ already lowered estimates. Excluding China, revenue from the vaccine increased 14%, the company said. Merck’s shares have ...

Excluding the impact of foreign exchange rates, sales rose 1%, Merck said. Net earnings rose 7% to $2.01 per share. Sales of Gardasil, a vaccine that prevents cancers caused by the human ...

Vaccine portfolio performance included GARDASIL sales of $1.3 billion ... through a licensing agreement with Hengrui Pharma. Merck maintained its 2025 full-year revenue guidance of $64.1 billion ...

Winrevair and Capvaxive and strong performance of the Animal Health segment were partially offset by lower sales of the HPV vaccine Gardasil in China. Keytruda, the biggest product in Merck’s ...

Robert F. Kennedy Jr., the secretary of the Department of Health and Human Services, has long criticized HPV vaccines, particularly Gardasil, made by Merck, which is the HPV vaccine used in the U ...

Merck said today its first-quarter adjusted profit rose 7% as lower costs helped offset a 2% decline in sales, reflecting a January decision to pause shipments of its Gardasil vaccine to China due ...

225,000-square-foot manufacturing plant slated to produce bulk substance for its HPV vaccine Gardasil. Merck built the new plant on a 262-acre campus it has occupied since 2004, where the pharma ...

Meanwhile, a continuous headwind dragging down Merck’s sales is the sluggish demand for HPV vaccine Gardasil in China. With sales crashing 40% over the first quarter to $1.3 billion, the company ...